Sophiris Bio Stock Forecast, Price & News

0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $0.03
50-Day Range
MA: $0.03
52-Week Range
Now: $0.03
Volume58,210 shs
Average Volume395,154 shs
Market Capitalization$1.01 million
P/E RatioN/A
Dividend YieldN/A
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:SPHS
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.01 million
Next Earnings DateN/A
OptionableNot Optionable


Sophiris Bio Inc (SPHS)
October 24, 2020 |  nasdaq.com
Sophiris Bio, Inc. (SPHS)
August 19, 2020 |  ca.finance.yahoo.com
Sophiris Bio To Shut Down Operations
May 18, 2020 |  finance.yahoo.com
Sophiris Bio Inc.
April 25, 2020 |  www.barrons.com
Sophiris to delist; shares plummet 42% after hours
March 10, 2020 |  seekingalpha.com
Sophiris Bio Announces Nasdaq Delisting
March 10, 2020 |  finance.yahoo.com
SPHS Feb 2020 2.500 call
February 22, 2020 |  finance.yahoo.com
Sophiris Bio files for equity offering
November 13, 2019 |  seekingalpha.com
Sophiris Bio secures $4M capital raise
August 27, 2019 |  seekingalpha.com
Sophiris Bio EPS beats by $0.04
August 9, 2019 |  seekingalpha.com
See More Headlines


Overall MarketRank

0.13 out of 5 stars

Medical Sector

1821st out of 2,010 stocks

Pharmaceutical Preparations Industry

727th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sophiris Bio (OTCMKTS:SPHS) Frequently Asked Questions

What stocks does MarketBeat like better than Sophiris Bio?

Wall Street analysts have given Sophiris Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sophiris Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sophiris Bio?

Sophiris Bio saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,000 shares, an increase of 1,900.0% from the February 28th total of 100 shares. Based on an average daily trading volume, of 176,800 shares, the short-interest ratio is currently 0.0 days.
View Sophiris Bio's Short Interest

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.02.
View Sophiris Bio's earnings history

How has Sophiris Bio's stock been impacted by Coronavirus?

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SPHS shares have decreased by 87.6% and is now trading at $0.0285.
View which stocks have been most impacted by COVID-19

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the following people:
  • Mr. Randall E. Woods, Pres, CEO & Director (Age 69, Pay $537.28k)
  • Mr. Peter T. Slover, Chief Financial Officer (Age 46, Pay $358.31k)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
  • Dr. James Joseph Beesley, Sr. Director of Investor Relations (Age 49)
  • Mr. Iain R. Mant, Corp. Sec.

Who are some of Sophiris Bio's key competitors?

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the OTCMKTS under the ticker symbol "SPHS."

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.03.

How much money does Sophiris Bio make?

Sophiris Bio has a market capitalization of $1.01 million.

How many employees does Sophiris Bio have?

Sophiris Bio employs 6 workers across the globe.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is www.sophirisbio.com.

Where are Sophiris Bio's headquarters?

Sophiris Bio is headquartered at 1258 PROSPECT STREET, LA JOLLA CA, 92037.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The company can be reached via phone at 858-777-1760 or via email at [email protected]

This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.